Tilray Brands delivered record second-quarter results, reporting revenue of $221 million, up 12% year-over-year, driven by strong performance in its Beverage Alcohol and Wellness segments. The company narrowed its loss per share to $0.14, a marked improvement from a loss of $1.00 in the prior-year period. Gross margin expanded by 450 basis points to 38%, reflecting favorable product mix and cost efficiencies in cultivation and manufacturing operations.

Tilray exited the quarter with a cash balance of $190 million and reduced net debt by 15% sequentially, resulting in a debt-to-equity ratio of just 0.15. Free cash flow turned positive at $8 million, compared with an outflow of $12 million in Q2 2025. Management highlighted disciplined inventory controls and working capital initiatives as key drivers of the cash conversion improvement.

Following the earnings release, a majority of analysts upgraded their outlook for Tilray, citing accelerating earnings momentum and expanding distribution agreements. The company announced new partnerships with two major international beverage producers, expected to add 200,000 cases of branded adult-use product to its distribution network over the next 12 months. Product innovation in vape and edibles categories was also singled out as a catalyst for market share gains.

A recent executive directive to reschedule cannabis to Schedule III is poised to allow companies like Tilray to deduct standard business expenses under Section 280E tax rules. Management estimates that this change could improve annual profitability by $25 million to $35 million once fully implemented. Investors are watching for IRS guidance on implementation timelines, which could unlock significant cash flow upside later this year.